International real-world study of DLL3 expression in patients with small cell lung cancer

Author
Pauwels, Patrick
Penault-Llorca, Frederique
Almarez, Todd
Wu, Meijing
Hader, Carlos
Miljkovic, Darko
Gosney, John
Biesma, Bonne
Brcic, Luka
Sailer, Verena
Rojo, Federico
Corassa, Marcelo
Mavroudis, Dimitrios
Oz, Aysim Buge
Metadata
Show full item record
Abstract
Objectives: Expression of the Notch-family ligand delta-like protein 3 (DLL3), a potential therapeutic target in small cell lung cancer (SCLC), has not been assessed in the real-world setting. To identify the real-world utility of DLL3 as an SCLC therapeutic target, we performed the largest retrospective international noninterventional study to date to evaluate DLL3 prevalence in SCLC patients.
URI
http://hdl.handle.net/20.500.12627/3657
https://doi.org/10.1016/j.lungcan.2020.07.026
Collections